No data to show
XNAS
GHRS
Market cap625mUSD
Apr 04, Last price
10.09USD
1D
2.33%
1Q
11.74%
IPO
-48.52%
Name
GH Research PLC
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-36m
L+398.77%
CFO
-42m
L+26.84%
Profile
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 41,501 | 30,601 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (41,501) | (30,601) | ||||
NOPBT Margin | ||||||
Operating Taxes | (15,321) | |||||
Tax Rate | ||||||
NOPAT | (41,501) | (15,280) | ||||
Net income | (35,587) 398.77% | (7,135) -22.54% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 15 | |||||
BB yield | 0.00% | |||||
| Debt | ||||||
Debt current | 255 | 343 | ||||
Long-term debt | 993 | 1,605 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 1,868 | |||||
Net debt | (181,376) | (220,754) | (251,679) | |||
| Cash flow | ||||||
Cash from operating activities | (42,285) | (33,336) | (26,199) | |||
CAPEX | (49) | (100) | (67) | |||
Cash from investing activities | 65,135 | (54,100) | (84,688) | |||
Cash from financing activities | (304) | (204) | ||||
FCF | 321 | (42,473) | (14,978) | |||
| Balance | ||||||
Cash | 149,324 | 161,560 | 165,955 | |||
Long term investments | 33,300 | 61,142 | 85,724 | |||
Excess cash | 182,624 | 222,702 | 251,679 | |||
Stockholders' equity | (112,512) | (72,495) | (41,632) | |||
Invested Capital | 292,087 | 292,437 | 291,448 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 52,023 | 52,021 | ||||
Price | 7.00 20.69% | 5.80 -40.33% | 9.72 -58.34% | |||
Market cap | 301,731 -40.33% | 505,643 -58.34% | ||||
EV | 80,977 | 253,964 | ||||
EBITDA | 315 | (41,186) | (30,554) | |||
EV/EBITDA | ||||||
Interest | 723 | 8,098 | ||||
Interest/NOPBT | ||||||